Loading...
|
Please use this identifier to cite or link to this item:
http://ir.nhri.org.tw/handle/3990099045/4937
|
| Title: | Longer-term assessment of trastuzumab-related cardiac adverse events in the herceptin adjuvant (HERA) trial |
| Authors: | Procter, M;Suter, TM;de Azambuja, E;Dafni, U;van Dooren, V;Muehlbauer, S;Climent, MA;Rechberger, E;Liu, TW;Toi, M;Coombes, RC;Dodwell, D;Pagani, O;Madrid, J;Hall, M;Chen, SC;Focan, C;Muschol, M;van Veldhuisen, DJ;Piccart-Gebhart, MJ |
| Contributors: | National Institute of Cancer Research |
| Abstract: | PURPOSE We investigated the incidence of cardiac adverse events in patients with early breast cancer in the Herceptin Adjuvant (HERA) trial who were treated with 1 year of trastuzumab after completion of (neo)adjuvant chemotherapy. PATIENTS AND METHODS The HERA trial is a three-group, randomized trial that compared 1 year or 2 years of trastuzumab with observation in women with human epidermal growth factor receptor-2 (HER2) -positive early breast cancer. Eligible patients had normal left ventricular ejection fraction (LVEF; >/= 55%) after completion of (neo)adjuvant chemotherapy with or without radiotherapy. Cardiac function was monitored throughout the trial. This analysis considers patients randomly assigned to 1 year of trastuzumab treatment or observation. Results There were 1,698 patients randomly assigned to observation and 1,703 randomly assigned to 1 year of trastuzumab treatment; 94.1% of patients had been treated with anthracyclines. The incidence of discontinuation of trastuzumab because of cardiac disorders was low (5.1%). At a median follow-up of 3.6 years, the incidence of cardiac end points remained low, though it was higher in the trastuzumab group than in the observation group (severe CHF, 0.8% v 0.0%; confirmed significant LVEF decreases, 3.6% v 0.6%) In the trastuzumab group, 59 of 73 patients with a cardiac end point reached acute recovery; of these 59 patients, 52 were considered by the cardiac advisory board (CAB) to have a favorable outcome from the cardiac end point. CONCLUSION The incidence of cardiac end points remains low even after longer-term follow-up. The cumulative incidence of any type of cardiac end point increases during the scheduled treatment period of 1 year, but it remains relatively constant thereafter. |
| Date: | 2010-07 |
| Relation: | Journal of Clinical Oncology. 2010 Jul;28(21):3422-3428. |
| Link to: | http://dx.doi.org/10.1200/jco.2009.26.0463 |
| JIF/Ranking 2023: | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0732-183X&DestApp=IC2JCR |
| Cited Times(WOS): | https://www.webofscience.com/wos/woscc/full-record/WOS:000280003700005 |
| Cited Times(Scopus): | http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=77955284228 |
| Appears in Collections: | [劉滄梧] 期刊論文
|
Files in This Item:
| File |
Description |
Size | Format | |
|---|
| PUB20530280.pdf | | 161Kb | Adobe PDF | 615 | View/Open |
|
All items in NHRI are protected by copyright, with all rights reserved.
|
